Cabaletta Bio CABA 深 沪
等待开盘 12-16 09:30:00 美东时间
2.39
+0.030
+1.27%
华盛通- 最 高2.455
- 今 开2.40
- 成交量 181.66万股
- 最 低 2.33
- 昨 收 2.36
- 总市值 2.19亿
- 52周最高 3.67
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.9857
- 委 比 -71.71%
- 总股本 9146.52万
- 历史最高 26.35
- 量 比 1.03
- 振 幅 5.30%
- 历史最低 0.59
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
11-27 04:13
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
11-05 03:25
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Cabaletta Bio will participate in several investor conferences in November and December 2025, including Guggenheim’s Healthcare Innovation Conference, TD Cowen Immunology & Inflammation Summit, Jefferies Global Healthcare Conference, Evercore Healthcare Conference, and Citi’s Global Healthcare Conference. The company will host webcasted fireside chats and investor meetings at these events. The live webcasts and replays can be accessed via the com...
11-04 13:00
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
11-01 01:06
Cabaletta Bio Announces Clinical Data And Development Updates Across RESET-Myositis, RESET-SSc And RESET-SLE Trials Evaluating Rese-Cel
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no
10-27 19:10
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio announced positive clinical data for rese-cel in treating patients with myositis, systemic sclerosis (SSc), and lupus. In the Phase 1/2 DM/ASyS cohort, all patients meeting inclusion criteria achieved major clinical responses without immunomodulators. A registrational trial for DM/ASyS is planned with 14 patients and a 16-week endpoint. In SSc, all patients with sufficient follow-up showed transformative responses off immunomodulato...
10-27 11:00
High Tide Celebrates Four Years of the Cabana Club
The Company Raises Its Long-Term Targets to 3 Million Cabana Club Members and 350 Canna Cabana Locations Across Canada Canna Cabana Named Canada's Most Recognizable Cannabis Retailer CALGARY...
10-21 20:00
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
Cabaletta Bio appoints Steve Gavel as Chief Commercial Officer, who brings extensive CAR T experience from Legend Biotech. Gavel will lead global commercial strategy for rese-cel, with a BLA submission expected in 2027. He previously led the successful launch of CARVYKTI® at Legend Biotech and has a strong track record in commercializing cell therapies. The company anticipates Gavel's leadership will enhance the commercialization efforts for rese...
10-14 12:00
Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Icon (ICLR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
10-14 01:50
